Precision-medicine approach could improve accuracy of PSA-based prostate cancer screening tests

A new study led by researchers at UC San Francisco and Kaiser Permanente has identified genetic predictors of normal prostate-specific antigen (PSA) levels in healthy men, which could be used to improve the accuracy of PSA-based prostate cancer screening tests.

Until recently, PSA tests for prostate cancer were considered an exemplar of successful early cancer detection leading to improved treatment outcomes. But over the past five years, a series of studies has suggested that the tests are not sensitive enough: frequent false positives lead to too many unnecessary medical procedures, and false negatives give men a false sense of security. In 2012, the test was given a "D" rating by the U.S. Preventive Task Force, and the test is no longer covered by some insurers.

"In the few years that PSA testing has become less popular, the use of the test has declined and the number of prostate cancer diagnoses has dropped," said John Witte, PhD, a UCSF professor of epidemiology and biostatistics and of urology, and co-senior author of the new study. "Disturbingly, some of the cases that are detected are now being diagnosed at a later stage, making successful treatment less likely. It's a big conundrum for the field."

One of the problems with current PSA tests is that they are a one-size-fits-all measurement of a protein that men naturally produce at different levels. The new genome-wide association study -- led by Witte and co-senior author Stephen K. Van Den Eeden, PhD, a research scientist at Kaiser Permanente Division of Research and professor of urology at UCSF -- suggests that the PSA test could regain its place in cancer prevention by factoring in genetic variations that affect the amount of PSA different men naturally produce.

Key to the study, which was published Jan. 31, 2017 in the online-only journal

"The unique setting of Kaiser Permanente allowed us to link every man in the study to our electronic clinical data and determine not just that they had a test, but also the level and frequency of testing over many years," said Van Den Eeden.

Using this large and rich study population, Witte's group was able to identify 40 genetic regions, or loci, that together predict nearly 10 percent of normal variation in PSA levels in men who do not have cancer.

The authors also determined that the rest of the genomic sites studied in the paper explained an additional 32 percent of normal PSA variation, though the study was not sensitive enough to identify the specific genetic loci responsible for this additional variation. The results suggest that even more genetic predictors of PSA levels are likely to be uncovered by future studies, the authors said.

Understanding a given patient's genetic predisposition to high PSA could allow physicians to better evaluate test results to predict the patient's actual risk of prostate cancer, according to Witte, either by normalizing the results of PSA screens based on each individual's natural PSA levels or by adjusting the threshold used to determine if a test result should trigger further testing, such as a prostate biopsy.

Thomas J. Hoffman, PhD, and Michael N. Passarelli, PhD, of UCSF were lead authors on the new study. See the paper online for a full list of authors and funding sources for the study.

"Despite the flaws of PSA testing, it does have value as a diagnostic tool," Witte said. "If we want to improve PSA as a useful diagnostic, we need to fold personalized genetics into medical decision-making. We need to be able to tell patients - this is a high PSA value for you, not just for the average person."

Comments

  1. Chris O'Neill Chris O'Neill Australia says:

    "this is a high PSA value for you, not just for the average person"

    This is a long, long way from showing that such a screening test will save lives. A randomised controlled trial proving the saving of lives is necessary before any harmful treatment motivated by such screening is done. This will not happen for many years, if ever.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Comet supercomputer reveals the mechanical process of cancer growth